| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
COMPASS Pathways Plc - American Depository Shares$12.53
+0.44 (+3.7%)
C 43Pipeline Score Overvalued Biotech · Commercial
Market Cap
1.59 B
EPS
-2.15
P/E Ratio
-
Value Trade
41.21 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
26.48 M
Operating CF
-47.94 M
Total Assets
531.74 M
Total Liabilities
205.05 M
Equity
326.69 M
D/E Ratio
12,345
14.11 %
Week
26.92 %
1 Month
43.5 %
3 Month
127.12 %
6 Month
-67.01 %
5 Year
-49.53 %
All Time
Cash Data
Cash Position
466.01 M
Monthly Burn
15.98 M
Runway
28 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
3.62 M
52 Week Range
2.25 - 12.24
% held by Insiders
4.58 %
% held by Institutions
66.18 %
Enterprise Value
1.18 B
Total Shares
134.92 M
Short %
5.69 %
Float Shares
128.74 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
C43
Pipeline Score $635M
Pipeline ValueOvervalued
Valuation Signal3
Drugs Scored0.4x
rNPV / MCap Top 65%
Micro Cap (rank 318 of 905)
Percentile RankCOMPASS Pathways Plc - American Depository Shares carries a moderate pipeline score (43/100), with $1.6B risk-adjusted pipeline value, led by Psilocybin in Major Depressive Disorder (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Psilocybin Small molecule | Major Depressive Disorder | Phase 3 | NCT05733546 | 54% | $1.5B | ACTIVE NOT_RECRUITING | 122 | SLOW | B (69) | Sep 1, 2025 | LOW_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
COMP360 | treatment-resistant depression | Phase 3 | 2025-06-23 | |||
COMP360 | treatment-resistant depression | Phase 3 | 2025-06-23 | |||
COMP360 | treatment-resistant depression | Phase 3 | 2025-06-23 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CMPS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
CMPS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CMPS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CMPS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CMPS Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
CMPS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CMPSCompass Pathways Elects Kathleen Tregoning to Board of Directors
Compass Pathways has announced the election of Kathleen Tregoning to its Board of Directors. This decision reflects the company's commitment to enhancing its governance and leadership. Tregoning's experience is expected to contribute positively to the strategic direction of Compass Pathways.
Read more →CMPSCompass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 2026
Compass Pathways is scheduled to participate in the Jefferies Global Healthcare Conference on June 3, 2026. This event will provide a platform for the company to discuss its initiatives and developments in the healthcare sector. Further details regarding the presentation and topics to be covered have not been disclosed.
Read more →CMPSCompass Pathways to Participate in RBC Capital Markets Global Healthcare Conference on May 19-20, 2026
Compass Pathways is set to participate in the RBC Capital Markets Global Healthcare Conference scheduled for May 19-20, 2026. This event will provide a platform for the company to discuss its developments and strategies in the healthcare sector. Further details regarding the presentation or topics to be covered have not been disclosed.
Read more →CMPSCompass Pathways Announces First Quarter 2026 Financial Results and Business Highlights
Compass Pathways has released its financial results for the first quarter of 2026, highlighting key business developments. The article provides insights into the company's performance and strategic initiatives during this period. However, specific details regarding financial figures or business highlights are not disclosed in the text provided.
Read more →CMPSCompass Pathways to Announce First Quarter 2026 Financial Results on May 13, 2026
Compass Pathways plc will announce its first quarter 2026 financial results on May 13, 2026. The announcement will be followed by a conference call at 8:00 am ET. The company is focused on developing innovative treatments for mental health, particularly through its investigational COMP360 treatment.
Read more →CMPSCompass Pathways Collaborates with Osmind to Advance Independent Clinic Readiness for Psychedelic Treatments
Compass Pathways has partnered with Osmind to prepare independent clinics for potential psychedelic treatments, specifically the investigational COMP360 psilocybin therapy. This collaboration aims to address operational and clinical needs, ensuring safe and effective delivery of treatments. Both companies seek to establish scalable care models for mental health conditions.
Read more →CMPSCompass Pathways to Participate in Needham Virtual Psychedelics Forum on April 27, 2026
Compass Pathways is set to participate in the Needham Virtual Psychedelics Forum scheduled for April 27, 2026. This event will likely focus on advancements and discussions in the psychedelics sector, although specific details about their participation are not provided in the article.
Read more →CMPSCompass Pathways Announces U.S Grant Program for the Creation of Post-Approval COMP360 Provider Training
Compass Pathways has announced a new grant program aimed at creating training for providers following the approval of COMP360. This initiative is designed to support healthcare professionals in delivering effective treatment. The program highlights the company's commitment to enhancing accessibility and education surrounding their therapy.
Read more →CMPSCompass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 7, 2026
Compass Pathways plc announced the granting of equity awards to seven newly hired non-executive employees under its 2026 Inducement Plan. The awards include options to purchase shares and restricted share units, with vesting contingent on continued employment. The company is focused on innovative mental health treatments, particularly its investigational COMP360 psilocybin treatment, which has received Breakthrough Therapy designation from the FDA.
Read more →CMPSCompass Pathways to Attend Needham Virtual Healthcare Conference on April 14, 2026
Compass Pathways is scheduled to participate in the Needham Virtual Healthcare Conference on April 14, 2026. This event will provide an opportunity for the company to engage with investors and discuss its ongoing projects and developments in the healthcare sector.
Read more →CMPSCompass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Compass Pathways has announced new employee inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4). This move is part of their strategy to enhance employee retention and attract talent. The specifics of the grants and their potential impact on the company are currently unclear.
Read more →CMPSCompass Pathways Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Highlights
Compass Pathways has released its financial results for the fourth quarter and full year of 2025. The report includes key business highlights, though specific details on performance metrics were not disclosed. The announcement reflects the company's ongoing activities and strategic direction in the biopharma sector.
Read more →CMPSCompass Pathways Announces Exercise of $200 Million in Outstanding Warrants
Compass Pathways plc has announced the exercise of 35,059,448 warrants, raising around $200 million. The funds will support ongoing Phase 3 trials for its COMP005 and COMP006 treatments, as well as its Phase 2b/3 trial of COMP360 for PTSD. The company expects these proceeds to cover operational expenses through 2028.
Read more →CMPSCompass Pathways to attend TD Cowen 46th Annual Healthcare Conference in Boston, MA from March 2-4, 2026
Compass Pathways plc will attend the TD Cowen 46th Annual Healthcare Conference in Boston from March 2-4, 2026. The company will participate in a fireside chat on March 3 at 10:30 AM ET. Compass is dedicated to advancing mental health treatments, particularly with its investigational COMP360 synthetic psilocybin, which has received FDA Breakthrough Therapy designation.
Read more →CMPSCompass Pathways Launches Proposed $150.0 Million Public Offering
Compass Pathways has announced a proposed public offering of $150 million of American Depositary Shares. The offering is aimed at accelerating patient access to innovative mental health treatments, particularly its investigational COMP360 psilocybin treatment. The company has granted underwriters a 30-day option to purchase additional shares. However, the completion of the offering is subject to market conditions.
Read more →CMPSCompass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression
Compass Pathways announced the successful achievement of the primary endpoint in its Phase 3 COMP006 trial for COMP360, a psilocybin treatment for treatment-resistant depression. The trial showed a significant reduction in depression symptoms compared to lower doses. The company plans to discuss a rolling submission with the FDA, aiming for an NDA submission in Q4. The findings highlight the treatment's rapid onset and sustained efficacy.
Read more →CMPSCompass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials
Compass Pathways plc will announce new clinical data from two ongoing Phase 3 trials for its COMP360 treatment for treatment-resistant depression. The results will be released on February 17th at 6:30 am ET, followed by a webinar at 8:00 am ET. COMP360 has received Breakthrough Therapy designation from the FDA, highlighting its potential significance in mental health treatment.
Read more →Competitive Position
How CMPS ranks across every disease it competes inCompetitive Position is a premium feature
See how CMPS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial